Metronidazole Hikma Farmacêutica (Portugal) (Metronidazole)

The drug penetrates susceptible cells and its nitro group is reduced under low‑oxygen conditions, forming reactive radicals that damage DNA. This interferes with nucleic acid synthesis, leading to microbial cell death, which is why it is effective against anaerobic bacteria and certain protozoa.

The prescribed dose is determined by the treating clinician based on the specific infection, patient weight, age, renal and hepatic function, and severity of disease. No fixed regimen is provided here; the prescriber sets the appropriate dosing schedule.

Metronidazole is classified as pregnancy category B, indicating that animal studies have not shown risk but there are limited human data. It may be used when the potential benefit justifies the potential risk. Caution is advised during breastfeeding, and the prescriber should evaluate the risk‑benefit ratio.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Metronidazole is a nitroimidazole that specifically targets anaerobic organisms through DNA damage, offering rapid bactericidal activity. Compared with broad‑spectrum agents like clindamycin, it often has fewer drug‑interaction concerns and a well‑established safety profile, though resistance patterns and individual patient factors guide the choice of therapy.

The product should be stored at 2‑8 °C, kept refrigerated, protected from light, and must not be frozen. Maintaining the cold‑chain ensures stability and potency of the intravenous solution until it is administered.

Metronidazole Hikma Farmacêutica is supplied as an intravenous solution and is administered by slow infusion into a vein under the supervision of a qualified healthcare professional. The infusion rate and duration are determined by the prescriber based on the indication and patient condition.

Serious adverse events include seizures, peripheral neuropathy, and severe skin reactions such as Stevens‑Johnson syndrome. Patients should be monitored for neurological symptoms, new skin eruptions, or any signs of hypersensitivity, and therapy should be discontinued promptly if these occur.

Metronidazole should be avoided in individuals with a known hypersensitivity to the drug or other nitroimidazoles. Caution is also required for patients with severe hepatic impairment, and it should not be given concurrently with alcohol due to the risk of a disulfiram‑like reaction.